Evaluation of Risk Factors for Epilepsy in Pediatric Patients with Cerebral Palsy

Małgorzata Sadowska1, Beata Sarecka-Hujar2, Ilona Kopyta3

  • 1Department of Pediatrics and Developmental Age Neurology, Upper Silesian Center for Child's Health, 40-752 Katowice, Poland.

Brain Sciences
|July 30, 2020
PubMed

Insights

Maternal hypertension, neonatal convulsions, and cesarean delivery significantly increase the risk of epilepsy in children with cerebral palsy (CP). These factors are also associated with drug-resistant epilepsy in CP patients.

Area of Science:

  • Pediatric Neurology
  • Developmental Disabilities
  • Epileptology

Background:

  • Cerebral palsy (CP) is a leading cause of childhood motor disability, frequently co-occurring with epilepsy.
  • Epilepsy in CP patients is often drug-resistant, posing significant treatment challenges.
  • Understanding risk factors for epilepsy in CP is crucial for early intervention and management.

Purpose of the Study:

  • To investigate the association between various risk factors (preconception, prenatal, perinatal, neonatal, infancy) and epilepsy in pediatric CP patients.
  • To identify specific factors contributing to the development of drug-resistant epilepsy in this population.

Main Methods:

  • Retrospective analysis of 181 pediatric patients diagnosed with CP (aged 4-17 years).
  • Data collected on preconception, prenatal, perinatal, neonatal, and infancy factors.
  • Statistical analysis using STATISTICA 13.0 to determine risk factors and odds ratios (OR) for epilepsy and drug-resistant epilepsy.

Main Results:

  • Epilepsy was diagnosed in 56.35% of CP patients, with 43% of these cases being drug-resistant.
  • Maternal hypertension (OR=12.46) and cesarean delivery (OR=2.17) were significant risk factors for epilepsy.
  • Neonatal convulsions (OR=3.04) and maternal hypertension (OR=9.86) were strongly associated with drug-resistant epilepsy.

Conclusions:

  • Maternal hypertension, neonatal convulsions, and cesarean section delivery are key risk factors for epilepsy in children with CP.
  • These factors also significantly elevate the risk of developing drug-resistant epilepsy.
  • Identifying these risk factors can aid in proactive management and potentially reduce epilepsy incidence and severity in CP.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
693
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
113